Jennifer Eck


Jennifer Eck joined AstraZeneca in 2010 and is part of team responsible for leading global marketing applications and post approval variations for the VAXZEVRIA covid vaccine. She provides regulatory strategy and guidance, supporting acceleration during the pandemic.

Jennifer has over 17 years of Biologics experience specializing in monoclonal antibodies and therapeutic proteins. Her experience includes 7 years at Janssen Biotech Inc. managing regulatory strategy and content for post approval biologics and 11 years at Sanofi as CMC Scientific Writer coordinating and authoring INDs, NDAs, and BLAs as well as an analytical chemist. Jennifer received her M.S. in Regulatory Affairs/Quality Assurance from Temple University and a B.A. in Chemistry Education from the University of Delaware